|Bid||0.2001 x 900|
|Ask||0.2059 x 2200|
|Day's Range||0.1982 - 0.2150|
|52 Week Range||0.1600 - 1.2000|
|Beta (5Y Monthly)||1.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for SLRX
The deal "provides entry into the exciting field of protein degradation, a fast-growing area of cancer drug research that is attracting substantial interest from some of the world’s largest pharmaceutical companies because of the potential advantages of protein degraders, including the ability to go after previously undruggable cancer-promoting targets," said David Arthur, CEO of Salarius.
Salarius (SLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...